Postrenal transplant malignancy: An update for clinicians
When compared to the general population, solid organ transplant patients had a 2–3 times higher overall risk of cancer. The third most frequent cause of mortality in kidney transplant patients is posttransplant malignancy, with certain malignancies (melanoma, renal cell carcinoma, and posttransplant...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Indian Journal of Transplantation |
| Subjects: | |
| Online Access: | http://www.ijtonline.in/article.asp?issn=2212-0017;year=2023;volume=17;issue=4;spage=389;epage=396;aulast=Soni |
| _version_ | 1797245527013720064 |
|---|---|
| author | Renuka Soni Priyadarshi Ranjan |
| author_facet | Renuka Soni Priyadarshi Ranjan |
| author_sort | Renuka Soni |
| collection | DOAJ |
| description | When compared to the general population, solid organ transplant patients had a 2–3 times higher overall risk of cancer. The third most frequent cause of mortality in kidney transplant patients is posttransplant malignancy, with certain malignancies (melanoma, renal cell carcinoma, and posttransplant lymphoproliferative disease) occurring at significantly greater rates than in the general population. Longer lifespans for kidney transplant recipients necessitate close monitoring for posttransplant cancer. Immunosuppressant medicine and oncogenic infections appear to be significant factors in the development of cancer. With the existing arsenal of pharmacotherapy and the possibility for immunologic surveillance in the future, posttransplant treatment might be tailored to reduce the risk of posttransplant malignancy without affecting graft survival. This manuscript gives an outline of the occurrence, causative factors, surveillance, diagnosis, and treatment of posttransplant malignancy. The review focuses on the most prevalent cancers and the patients who are most at risk of developing them, including an overview of pathogenesis, the association of immunosuppressive medications with the development of cancer, and several proposed processes that explain why transplant recipients have a higher cancer risk. |
| first_indexed | 2024-04-24T19:28:19Z |
| format | Article |
| id | doaj.art-f9b817343d8a4a5387ae20d5576c6f62 |
| institution | Directory Open Access Journal |
| issn | 2212-0017 2212-0025 |
| language | English |
| last_indexed | 2024-04-24T19:28:19Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Transplantation |
| spelling | doaj.art-f9b817343d8a4a5387ae20d5576c6f622024-03-25T14:41:57ZengWolters Kluwer Medknow PublicationsIndian Journal of Transplantation2212-00172212-00252023-01-0117438939610.4103/ijot.ijot_60_23Postrenal transplant malignancy: An update for cliniciansRenuka SoniPriyadarshi RanjanWhen compared to the general population, solid organ transplant patients had a 2–3 times higher overall risk of cancer. The third most frequent cause of mortality in kidney transplant patients is posttransplant malignancy, with certain malignancies (melanoma, renal cell carcinoma, and posttransplant lymphoproliferative disease) occurring at significantly greater rates than in the general population. Longer lifespans for kidney transplant recipients necessitate close monitoring for posttransplant cancer. Immunosuppressant medicine and oncogenic infections appear to be significant factors in the development of cancer. With the existing arsenal of pharmacotherapy and the possibility for immunologic surveillance in the future, posttransplant treatment might be tailored to reduce the risk of posttransplant malignancy without affecting graft survival. This manuscript gives an outline of the occurrence, causative factors, surveillance, diagnosis, and treatment of posttransplant malignancy. The review focuses on the most prevalent cancers and the patients who are most at risk of developing them, including an overview of pathogenesis, the association of immunosuppressive medications with the development of cancer, and several proposed processes that explain why transplant recipients have a higher cancer risk.http://www.ijtonline.in/article.asp?issn=2212-0017;year=2023;volume=17;issue=4;spage=389;epage=396;aulast=Soniimmunosuppressionkaposi sarcomakidney transplantposttransplant lymphoproliferative diseaseposttransplant malignancyrenal cell carcinoma |
| spellingShingle | Renuka Soni Priyadarshi Ranjan Postrenal transplant malignancy: An update for clinicians Indian Journal of Transplantation immunosuppression kaposi sarcoma kidney transplant posttransplant lymphoproliferative disease posttransplant malignancy renal cell carcinoma |
| title | Postrenal transplant malignancy: An update for clinicians |
| title_full | Postrenal transplant malignancy: An update for clinicians |
| title_fullStr | Postrenal transplant malignancy: An update for clinicians |
| title_full_unstemmed | Postrenal transplant malignancy: An update for clinicians |
| title_short | Postrenal transplant malignancy: An update for clinicians |
| title_sort | postrenal transplant malignancy an update for clinicians |
| topic | immunosuppression kaposi sarcoma kidney transplant posttransplant lymphoproliferative disease posttransplant malignancy renal cell carcinoma |
| url | http://www.ijtonline.in/article.asp?issn=2212-0017;year=2023;volume=17;issue=4;spage=389;epage=396;aulast=Soni |
| work_keys_str_mv | AT renukasoni postrenaltransplantmalignancyanupdateforclinicians AT priyadarshiranjan postrenaltransplantmalignancyanupdateforclinicians |